Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02346149
Other study ID # SNSF132913
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date June 2015
Est. completion date January 31, 2019

Study information

Verified date July 2019
Source Centre Hospitalier Universitaire Vaudois
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Diabetes Mellitus (DM) includes several metabolic diseases all characterized by high sugar levels in the blood. Although diabetic nephropathy is widespread, its underlying pathophysiological mechanisms remain poorly understood and, so far, little progress has been made to prevent the development of diabetic nephropathy and to delay kidney functions decline.

Increasing amount of data based on animal studies support the pathogenic role of tissue hypoxia in the development and progression of diabetic nephropathy. Blood Oxygenation-Level Dependent Magnetic Resonance Imaging (BOLD-MRI) is increasingly used in research to measure cortical and medullary oxygenation in a non-invasive manner. Interestingly, in two cross-sectional clinical studies, we have recently found a positive correlation between high circulating blood glucose levels and cortical R2* levels in type 2 DM patients. This discovery suggests that an increase in glycemia might acutely decrease renal tissue oxygenation.

The goal of this study is to investigate the impact of serum glucose on renal tissue oxygenation in healthy subjects and subjects with glucose intolerance.


Description:

Therefore, we plan to recruit 10 healthy subjects and 10 glucose intolerant patients with preserved kidney functions and to perform repetitive BOLD-MRI, before and after the administration of IV glucose. This will allow us to study the influence of hyperglycemia as a single factor, regardless of inflammation, oxidative stress and medical treatments, such as oral hypoglycemic agents and/or insulin, which are confounding factors present in all DM patients.

The main hypothesis of the project is that acute hyperglycemia could be partially responsible for renal tissue hypoxia detected in diabetic nephropathy cases.

In this study we will include 60 participants with a family history of diabetes, with a Body Mass Index (BMI) over 25 kg / m2 and/or having glucose intolerance. Each participant will undergo an initial glucose tolerance test. In total, we will select 10 participants with impaired glucose tolerance and 10 healthy subjects (matched for sex and age), to be included as control group.

Selected subjects will return for a third visit at CHUV (V3): they will start at home with an oral hydration protocol (load dose of 3 ml / kg at 8:00 am, followed by 1 ml / kg every hour between 9:00 am and 3:00 pm to avoid as much as possible changes in kidney perfusion). Patients will arrive at the Department of Nephrology and Hypertension (CHUV) at 11.00 am. In this occasion, two catheters will be placed into each patient's arm. Later, participants will be escorted to the Radiology Department to undergo four renal oxygenation imaging (between 1:00 pm and 2:00 pm) by the mean of BOLD-MRI technique. During this period, patients and control subjects will lie down and are not allowed to stand up. At T0, they will receive a bolus (0.75 ml / kg) of glucose 20%. Subsequently, four BOLD-MRI scans, together with blood tests, will be performed at T0, T1 (+10 min), T2 (+20 min), T3 (+30 min). Sodium intake will be measured by 24 hours urinary collection the day before V3 (sodium is known to influence R2*).


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date January 31, 2019
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Positive family history of diabetes

- BMI > 25 kg / m2

- eGFR > 60 ml / min / 1.73 m2

- Understanding and signing the informed consent

Exclusion Criteria:

- Documented cardiac disease

- Documented liver failure

- Renal malformations, kidney diseases or documented renal artery stenosis

- History of organ transplantation

- Significant comorbidities compromising life expectancy

- Anemia

- Type 1 or 2 diabetes

- Psychiatric illness

- Contraindication to MRI

- Pregnancy or breastfeeding

- Chronic drug intake such as antihypertensive (except for beta blockers and calcium antagonists), non steroidal anti-inflammatory drugs, diuretics or oral antidiabetics

- Blood donation 2 months before the MRI investigation day

Study Design


Related Conditions & MeSH terms


Intervention

Other:
glucose 20%
Intravenous infusion (0.75 ml / kg) over 1 min

Locations

Country Name City State
Switzerland Department of Nephrology, Centre Hospitalier Universitaire Vaudois Lausanne Vaud

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Vaudois

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Pruijm M, Hofmann L, Zanchi A, Maillard M, Forni V, Muller ME, Wuerzner G, Vogt B, Stuber M, Burnier M. Blockade of the renin-angiotensin system and renal tissue oxygenation as measured with BOLD-MRI in patients with type 2 diabetes. Diabetes Res Clin Pract. 2013 Feb;99(2):136-44. doi: 10.1016/j.diabres.2012.11.004. Epub 2012 Dec 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cortical and medullary renal R2* MRI signal variation, before, during and after an induced hyperglycemic state Four R2* imaging will be performed during an investigation day between 1:00 pm and 2:00 pm
Primary Intergroup variability of MRI R2* signal, before, during and after an induced hyperglycemic state Four R2* imaging will be performed during an investigation day between 1:00 pm and 2:00 pm
See also
  Status Clinical Trial Phase
Completed NCT01267448 - Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Phase 4
Recruiting NCT03775733 - Efficacy and Safety of Hydrolysed Red Ginseng Extract on Improvement of Hyperglycemia N/A
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Completed NCT00535600 - Effects of Bariatric Surgery on Insulin
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Recruiting NCT02885922 - The Effects of add-on Anti-diabetic Drugs in Type 2 Diabetic Patients
Recruiting NCT02885909 - Inpatient Blood Glucose Control in Taichung Veterans General Hospital Phase 4
Withdrawn NCT01488383 - Effect of Stevioside in Postpandrial Glucose in Healthy Adults N/A
Completed NCT02012465 - Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients Early Phase 1
Completed NCT01805414 - Breakfast Nutrition and Inpatient Glycemia N/A
Completed NCT01803568 - Skeletal Muscles, Myokines and Glucose Metabolism MYOGLU N/A
Completed NCT01810952 - The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Phase 4
Active, not recruiting NCT01247714 - Clinical Evaluation of a Specific Enteral Diet for Diabetics N/A
Not yet recruiting NCT00846144 - The Reduction in Glucose Stimulated Insulin Secretion Induced by Cytokines May be Prevented by Copper Addition - Studies in Diabetic Patients N/A
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Recruiting NCT00654797 - Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2 Phase 2
Completed NCT00468494 - Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia? N/A
Completed NCT00394407 - Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes Phase 4